Decreased choroidal thickness could increase VEGF

Article

Decreased choroidal thickness could increase vascular endothelial growth factor (VEGF) and cause tissue hypoxia.

Decreased choroidal thickness could increase vascular endothelial growth factor (VEGF) and cause tissue hypoxia.

Dr Giuseppe Querques et al., Department of Ophthalmology, University Vita Salute San Raffaele, Milan, Italy, studied a total of 63 eyes of 63 diabetic patients either without diabetic retinopathy (NDR), with diabetic retinopathy [nonproliferative diabetic retinopathy (NPDR)] and no clinically significant macular oedema (CSME).

The mean best-corrected visual acuity was 0.13 ± 0.25 LogMAR and the mean central macular thickness (CMT) was 272.5 ± 16.2 μm in 21 NDR eyes, 294.5 ± 23.5 μm in 21 NPDR/CSME− eyes, and 385.6 ± 75.1 μm in 21 NPDR/CSME+ eyes.

There were no differences in mean subfoveal choroidal thickness between each diabetic group. However, in each diabetic group the mean subfoveal choroidal thickness was significantly reduced compared to the control group.

An overall thinning of the choroid on EDI OCT was witnessed in diabetic eyes. This could lead to tissue hypoxia and could increase VEGF levels, meaning the blood-retinal barrier could break down and cause macular oedema.

The abstract for the study was printed in the Investigative Journal of Ophthalmology.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
Related Content
© 2025 MJH Life Sciences

All rights reserved.